Fulcrum is Vertex’s second acquisition since partnering with Wind Point in August of 2021 Based in Chicago, Wind Point Partners has about $4 billion in assets under management Wind Point invests in ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Fresh leaks on Google's Vertex AI platform point to an imminent launch for Gemini 3 Pro and Nano Banana 2, as the company ...
Breakwater was established in 2019 Wind Point Partners targets investments in the consumer products, industrial products and business services sectors The firm has approximately $6 billion in assets ...
Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares ...
Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF ...
Vertex Capital Management has migrated its Vertex Evolution UCITS Fund to Point Nine's Circle.2 live and cloud-based service. Circle.2 provides cloud-based trade reconciliation and settlement services ...
The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback